Institutional members access full text with Ovid®

Share this article on:

Comparison of FDG PET/CT and Gadolinium-Enhanced MRI for the Detection of Bone Metastases in Patients With Cancer: A Meta-analysis

Duo, Jian MD, PhD*; Han, Xiuxin MD, PhD*; Zhang, Li MD; Wang, Guowen MD*; Ma, Yulin MD*; Yang, Yun MD*

doi: 10.1097/RLU.0b013e3182817af3
Original Articles

Objective At present, the differences in the efficacy between PET/CT and MRI for the detection of bone metastases in patients with cancer have not been clearly delineated. We performed a meta-analysis to compare the performance of FDG PET/CT with that of gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer.

Methods Studies about PET/CT and MRI for the detection of bone metastases were systematically searched in the MEDLINE, EMBASE, and EBM Review databases. We calculated sensitivities, specificities, diagnostic odds ratios, positive likelihood ratios, negative likelihood ratios (NLR), and constructed summary receiver operating characteristic curves using bivariate regression models for PET/CT and MRI, respectively.

Results Across 9 studies (1116 patients), FDG PET/CT has similar patient-based sensitivity (0.803 vs 0.837), specificity (0.989 vs 0.977), diagnostic odds ratio (309.0 vs 221.9), positive likelihood ratio (61.7 vs 37.0), and negative likelihood ratio (0.200 vs 0.167) with gadolinium-enhanced MRI. Areas under the curve with 95% confidence interval for FDG PET/CT and gadolinium-enhanced MRI were 0.99 (0.98–0.99) and 0.98 (0.97–0.99), respectively.

Conclusions FDG PET/CT and gadolinium-enhanced MRI have excellent diagnostic performance for the detection of bone metastases in patients with cancer.

From the Departments of *Bone and Soft Tissue Tumors and †Gynecology Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China.

Received for publication September 2, 2012; revision accepted November 30, 2012.

Drs Duo and Han contributed equally to this work as first author.

Conflicts of interest and sources of funding: none declared.

Reprints: Jian Duo, MD, PhD, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, He Xi District, Tianjin 300060, People’s Republic of China. E-mail: duojian101@sohu.com.

© 2013 by Lippincott Williams & Wilkins